Emgality® ▼ (galcanezumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Emgality Summary of Product Characteristics (SmPC)

Emgality®▼ (galcanezumab) Device: Information on Air Bubbles

It is normal to have air bubbles in the pen or syringe. The medicine is injected under the skin (subcutaneous injection).

Additional Information

The presence of the air bubble is due to the syringe manufacturing process. It will not cause harm or affect the accuracy of the dose.1

Patients should not try to remove or expel the air bubble in the device. Removal of the air bubble before injecting is not necessary and not recommended.1

The instructions for using the pen or syringe included with the Package Leaflet, must be followed carefully. The pre-filled pen and pre-filled syringe is for total use only.2

After training, patients may self-inject galcanezumab if a healthcare professional determines that it is appropriate.3

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Emgality [instructions for use]. Eli Lilly Nederland B.V., The Netherlands.

3. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: February 13, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question